Skip to Content
MDPIMDPI

Advanced

DermatopathologyDermatopathology
PDF
  • Review
  • Open Access

16 January 2026

19 Pages

Behçet-like Syndromes: A Comprehensive Review

,
,
,
and
1
Allergy and Clinical Immunology Service, Regional Hospital of Locarno, Ente Ospedaliero Cantonale (EOC), 6600 Locarno, Switzerland
2
Department of General Internal Medicine, Regional Hospital of Locarno, Ente Ospedaliero Cantonale (EOC), 6600 Locarno, Switzerland
3
Faculty of Biomedical Sciences, Università della Svizzera Italiana (USI), 6962 Lugano, Switzerland
4
Department of General Internal Medicine, Regional Hospital of Mendrisio, Ente Ospedaliero Cantonale (EOC), 6850 Mendrisio, Switzerland
Dermatopathology2026, 13(1), 7;https://doi.org/10.3390/dermatopathology13010007
This article belongs to the Section Clinico-Pathological Correlation in Dermatopathology
Version Notes
Order Reprints

Simple Summary

Behçet-like syndromes (BLSs) are conditions that present with symptoms similar to Behçet’s disease—such as oral and genital ulcers, fever, skin lesions, joint pain, and intestinal involvement—but arise in association with other underlying disorders. These include monogenic immune defects, myeloproliferative diseases, infections, or reactions to specific medications. Because BLS can resemble Behçet’s disease but requires different treatments, recognizing the underlying cause is essential for proper management. In this review, we summarize all published cases of BLS up to January 2024, highlighting their clinical features, genetic findings, and therapeutic approaches. Understanding BLS as a distinct group of conditions may also provide insights into the mechanisms that drive Behçet’s disease itself.

Abstract

Background: Behçet-like syndrome (BLS) refers to the presence of Behçet’s disease (BD) features occurring in association with distinct clinical–pathological conditions such as inborn errors of immunity, myeloproliferative disorders, infections, or drug exposure. BLS may differ clinically from BD and is increasingly recognized as a separate entity. Distinguishing BLS from primary BD is essential for appropriate management, and studying BLS may provide insights into BD pathogenesis. Objectives: To summarize clinical features, treatments, and genetic abnormalities reported in BLS, we reviewed all published cases up to January 2024. Methods: A systematic search of PubMed, Scopus, and Embase was performed using the terms “Behçet-like syndrome”, “Behçet-like disease”, and “Pseudo-Behçet disease”. We included English-language reports of patients > 12 years old with a defined underlying etiology and Behçet-like manifestations, defined by ≥2 ICBD criteria and/or gastrointestinal involvement, mucosal ulcers, thrombosis, or non-recurrent disease. Epidemiological, clinical, laboratory, histological, and treatment data were extracted and analyzed descriptively. Results: Of 679 publications, 53 met inclusion criteria, comprising 100 patients with BLS. The median age was 44 years (IQR 22–52), with a female predominance (1:2). Fifty-three percent were from non-European countries. A genetic disorder was identified in 70% of cases, while HLA-B51 was present in 10%. Frequent manifestations included skin lesions (68%), fever (56%), intestinal involvement (43%), and joint symptoms (43%). Treatments included glucocorticoids (65%), conventional DMARDs (32%), and biologics (22%), mainly anti-TNF agents. Antiviral/antibiotic therapy was used in 9% and chemotherapy in 15%. Two patients with trisomy-8 MDS underwent allogeneic stem cell transplantation. Conclusions: Diverse conditions—including monogenic diseases, immune defects, myeloproliferative disorders, infections, and drug-related reactions—can produce Behçet-like features. Our findings highlight differences in clinical expression and treatment response across BLS etiologies. Recognizing BLS is essential for appropriate management and may contribute to a deeper understanding of BD pathogenesis and future targeted therapies.

1. Introduction

Behçet-like syndrome (BLS) is defined as the presence of Behçet syndrome features, or Behçet disease (BD), occurring in association with a distinct clinical and/or pathological defined entity, such as various inborn errors of immunity (IEI), including autoinflammatory conditions related to dysregulation of the nuclear factor kappa B (NF-κB) pathway (e.g., TNFAIP3, NFKB1, RELA, IKK gamma mutations) or DADA2, CSF2, and LIG4 mutations [1]. BLS has also been largely described in association with myeloproliferative and myelodysplastic disorders [1,2]. Moreover, some microbial infections, such as Mycobacterium Tuberculosis (MT) and viral infections, can trigger the onset of BLS in genetically susceptible subjects [3]. The development of a BLS has even been reported following drug administration [4].
The clinical symptoms in BLS—such as oral and genital aphthous ulcers, fever, skin lesions, arthralgia/arthritis, ocular inflammation, gastrointestinal ulceration, and vascular involvement—may occur before the onset of the associated diseases [5,6,7] or later on in the disease course [8,9], further expanding the phenotypic spectrum of the associated entities.
BLS does not exhibit specific or pathognomonic histopathological features. As in classical BD, biopsy findings are often nonspecific and may include neutrophilic infiltrates, lymphocytic vasculitis, or ulceration, but none of these patterns reliably distinguish BLS from BD or from other inflammatory or ulcerative conditions. For this reason, the diagnosis of BLS cannot rely on histopathology alone. Instead, it requires the coexistence of Behçet-like clinical manifestations together with a clearly identifiable underlying condition—such as a monogenic autoinflammatory disorder, myelodysplastic syndrome, infection, or drug-related immune dysregulation. Histopathology may support the exclusion of mimickers (e.g., pyoderma gangrenosum, Lipschütz ulcer), but it does not define BLS.
The treatment strategy of BLS differs based on the underlying aetiology: NSAIDs or traditional immunosuppressive therapies frequently fail to relieve the symptoms of BLS [10,11,12,13,14,15,16,17]. Thus, it is essential to distinguish BLS from primary BD in order to ensure appropriate treatment.
This review highlights the clinical characteristics, genetic alterations, and therapeutic approaches of all clinical cases of BLS and associated conditions published up to January 2024, aiming to better define the key features of BLS, particularly those linked to monogenic diseases. Such extensive analysis could enhance our understanding of the pathogenesis of BD and pave the way for further research into its pathophysiology and potential therapeutic targets.

2. Methods

We conducted a literature review of all relevant reports on patients affected by Behçet-like syndrome (BLS) and associated diseases by searching the PubMed, Scopus, and Embase databases in January 2024. The search terms included “Behçet-like syndrome”, “Behçet-like disease”, and “Pseudo-Behçet disease”, with a language restriction to English. We retrieved and reviewed all potentially relevant abstracts and examined the references of the obtained publications to identify additional reports. Non-peer-reviewed reports were excluded. We included only patients with a clearly defined etiological entity and Behçet-like disease, which was defined by the presence of at least two of the International Criteria for Behçet’s Disease (ICBD) [9] and/or a combination of gastrointestinal involvement, oral and/or genital aphthous ulcers, thrombosis, and/or the absence of demonstrated recurrence over time.
We excluded: (1) patients fulfilling full ISG or ICBD criteria for Behçet’s disease (BD) [9]; (2) pediatric cases < 12 years; (3) reports lacking a clearly defined underlying etiology; (4) non-English publications; (5) conference abstracts without sufficient clinical detail. We collected data on sex, age at diagnosis, underlying genetic disorders, clinical manifestations, diagnostic procedures, and treatments. Specifically, we gathered information on the following clinical features: non-infectious fever, skin abnormalities, arthritis, ocular manifestations, gastrointestinal symptoms, peripheral or central neurological involvement, venous or arterial thrombosis, associated diseases, diagnostic procedures, and treatments. Laboratory data were included, when available, encompassing blood counts, C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), serum creatine kinase levels, hepatitis C virus (HCV) and HIV serologies, immunological markers (anti-neutrophil cytoplasmic and antinuclear antibodies, cryoglobulinemia), and human leukocyte antigen B51 (HLA-B51) status. We also reviewed endoscopic abnormalities and histopathological findings. Because the evidence consisted exclusively of case reports and small case series, we assessed risk of bias using adapted CARE and JBI criteria, focusing on clarity of case definition, completeness of clinical description, diagnostic certainty, and reporting of outcomes. Given the descriptive nature of the data, no cases were excluded based on quality, but reporting limitations were considered when interpreting results.
Descriptive statistics were employed to ascertain the frequencies and central tendencies of the cohort. Data are expressed as median (interquartile range [IQR]: 25° and 75° percentiles) for quantitative variables and number (percentage) for categorical variables. To compare continuous variables across etiologic groups, we adopted the Kruskal–Wallis test, while for the categorical variables we used the Chi-square test.

3. Results

The database search identified 679 publications, of which 53 met the inclusion and exclusion criteria, reporting a total of 100 patients with Behçet-like syndrome (Table 1).
Table 1. Literature data referring to Behçet-like Syndrome patients.

Characteristics of Patients with Behçet-like Syndrome

The 100 patients included in this review illustrate that BLS represent a heterogeneous group of disorders sharing a Behçet-like phenotype but differing substantially in their underlying mechanisms and clinical expression. The median age at diagnosis was 44 years (IQR 22–52), with symptoms often beginning much earlier (median onset 25 years). Women were more frequently affected (61%), and over half of the cohort originated from non-European countries, particularly Turkey and Japan. Despite this geographic distribution, no ethnicity-specific clinical patterns emerged, and NF-κB–related mutations (A20, NEMO, RELA) appeared evenly distributed across populations.
A defined genetic abnormality was identified in 70% of cases, most commonly involving the NF-κB pathway (TNFAIP3, NFKB1, RELA, IKBKG), but also ADA2, CSF2, and LIG4. HLA-B51 positivity was uncommon (10%), supporting the notion that BLS differs immunogenetically from classical Behçet disease.
Fever was the most frequent systemic manifestation (56%), but its distribution varied markedly by etiology (Table 2 and Table 3). Fever was notably less frequent in the NEMO group and had a higher incidence in infectious diseases when compared to other etiologies.
Table 2. Clinical characteristics of patients (n = 100) with Behçet-like syndrome.
Table 3. Clinical manifestations in BLS in blue are clinical manifestations according to the international criteria for Behçet disease scoring system [9] (* p < 0.05).
Mucocutaneous involvement was nearly universal, but its expression varied:
Oral ulcers (including aphthous lesions) occurred in 88% of patients and were particularly prominent in monogenic NF-κB–related disorders (A20, NEMO, RELA).
Genital ulcers were less frequent (57%) but tended to cluster in NEMO-related and infection-associated BLS.
Skin lesions (68%) were dominated by pseudofolliculitis-like eruptions and erythema nodosum. Erythema nodosum was more common in infection-related BLS, reflecting a reactive inflammatory pattern. No cases of urticaria were reported, helping differentiate BLS from other autoinflammatory or allergic conditions. Pathergy was uncommon (11%) and did not distinguish etiologic groups. Joint involvement (43%) showed one of the clearest etiologic patterns:
A20 haploinsufficiency was strongly associated with arthromyalgia and polyarthritis (p = 0.030 and p = 0.010), suggesting a more systemic autoinflammatory phenotype.
NEMO-related BLS showed minimal articular involvement, reinforcing its mucocutaneous predominance. Gastrointestinal involvement was common across the cohort but showed a striking concentration in patients with hematologic disorders:
Inflammatory bowel disease–like features were present in 43% of all patients.
Trisomy 8–associated myelodysplastic syndromes showed the highest rates of intestinal ulceration, bleeding, and stenosis/obstruction.
A20-related disease also showed a tendency toward intestinal ulcers, though less severe than in hematologic BLS.
Ocular involvement (19%) was disproportionately represented in infection-related BLS, particularly tuberculosis-associated cases.
Neurologic manifestations (14%) were scattered across etiologies without a clear pattern.
Thrombosis occurred in 16% of patients, but reports rarely specified whether histopathology resembled classical Behçet vasculitis, limiting interpretation.
A minority of patients (6%) exhibited benign inflammatory lymphoproliferation mimicking PFAPA (Periodic Fever, Aphthous Stomatitis, Pharyngitis, Adenopathy), highlighting the overlap between autoinflammatory syndromes.
Table 2 and Table 3 highlight the distribution of symptoms and signs across the etiologic groups.
A total of 83% of patients received treatment. Glucocorticoids were administered to 65% of patients, and the conventional disease-modifying antirheumatic drugs (cDMARDs) were used in 32%, including colchicine, 5-aminosalicylic acid (5-ASA)/mesalazine, mycophenolate mofetil, dapsone, apremilast, and methotrexate. Some patients (9%) received antiviral and antibiotic therapy, whilst chemotherapy (azacitidine, venetoclax) was necessary in 15% of cases. The biologic disease-modifying antirheumatic drugs (bDMARDs) were used in 22% of patients, primarily anti-TNF-α (16 cases), followed by anti-IL1 (3 cases), anti-IL17 (2 cases), anti-IL23 (1 case), and anti-CD20 (1 case). Allogeneic hematopoietic stem cell transplantation was required in two cases due to trisomy 8 myelodysplastic syndrome.

4. Discussion

This review demonstrates that BLS encompasses a heterogeneous group of conditions that mimic BD but arise from distinct pathogenic mechanisms. Recognizing these patterns is essential because management differs substantially from classical BD.
Despite our systematic review of the literature and the broad heterogeneity of the reported clinical presentations, we were unable to propose a unified or universally applicable definition of Behçet-like syndrome (BLS). The conditions described share clinical features reminiscent of Behçet disease but do not fulfill PEDBD, ISG, or ICBD diagnostic criteria and occur in association with a wide range of underlying disorders. This variability currently prevents the formulation of formal diagnostic criteria or a standardized definition.
We support the current conceptualization of BLS as a clinical condition in which features typical or compatible with Behçet disease—such as recurrent oral or genital aphthosis, cutaneous lesions, arthritis, uveitis, vasculitis, or intestinal ulceration—occur in patients who do not fulfill established diagnostic criteria for BD and who present a clearly identifiable underlying etiology [9,56]. These etiologies include monogenic autoinflammatory disorders, inborn errors of immunity, myelodysplastic or myeloproliferative diseases, infections, or paradoxical reactions to biologic therapies [1,2,3,4,5,6]. The present literature review allows us to describe different subgroups of BLS, associated with different underlying aetiological mechanisms. Interestingly, each subgroup seems to have some distinctive clinical features (Figure 1). We discuss below the features of 4 different groups of BLS. In this framework, BLS represents a secondary or syndromic entity, heterogeneous in its causes and pathogenic mechanisms, yet unified by a clinical phenotype that resembles BD without constituting a primary form of the disease.
Figure 1. Clinical characteristics of patients with Behçet-like syndrome according to aetiology.

4.1. Genetically Related Behçet-like Syndrome

Genetic mutations play a significant role in the pathogenesis of BD, and several monogenic conditions mimic its clinical manifestations. The NF-κB signaling pathway is central to immune cell activation and inflammation (Figure 2). Genetic mutations affecting the NF-κB pathway, notably in genes like A20, NEMO, and RELA, are key contributors to BLS. Mutations in A20, a protein essential for suppressing NF-κB activity, lead to an imbalance in immune responses, causing spontaneous inflammation and an increased response to TNF-α, IL-1β, and IL-18, exacerbating inflammatory processes in BLS patients [12,13].
Figure 2. NF-kB signaling. NF-kB is activated, other than by antigen recognition, by TLR ligands and by many cytokines belonging to the TNFR and IL 1R families through two pathways: the canonical and the non-canonical pathways.
Monogenic disorders affecting the NF-κB pathway (A20, NEMO, RELA) can closely mimic BD. These mutations disrupt immune regulation and promote exaggerated responses to TNF-α, IL-1β, and IL-18 [12,13,14,15,16], resulting in a Behçet-like inflammatory phenotype. In our synthesis, A20 haploinsufficiency emerged as the most clinically expressive condition, with a combination of recurrent oral ulcers, genital aphthosis, polyarthritis, and gastrointestinal ulceration. The prominence of articular involvement in A20-related disease suggests a systemic autoinflammatory signature that differs from classical BD.
NEMO-related disease, in contrast, tended to present with mucocutaneous features and relatively limited systemic inflammation. RELA haploinsufficiency [13,15,18,19,21,52,57,58,59,60,61,62,63] showed an intermediate phenotype, with mucosal ulceration as the dominant feature. These observations reinforce the need to consider monogenic causes in early-onset, familial, or treatment-refractory Behçet-like presentations, as the therapeutic approach may differ substantially from BD-oriented immunosuppression.
Similarly, mutations in the ADA2 gene, underlying DADA2 disease, could also lead to recurrent oral/genital ulcers and other BD-like symptoms, complicating the diagnostic process and underscoring the need for genetic testing in atypical cases [20,64,65].
For monogenic BD-like diseases, particularly those involving NF-κB pathway mutations, therapies targeting inflammatory cytokines such as TNF-α or IL-1 may be beneficial. In cases where genetic mutations like A20, NEMO, DADA2 or RELA are identified, tailored therapies that modulate the immune response to prevent excessive inflammation should be prioritized [66].

4.2. Infection-Related Behçet-like Syndrome

Infections caused by viruses and mycobacteria can act as triggers for Behçet-like manifestations, particularly in genetically predisposed individuals. This observation supports the molecular mimicry hypothesis, whereby pathogens such as Mycobacterium tuberculosis (MT) and herpes simplex virus (HSV) share antigenic homology with host proteins, including heat shock protein 60 (HSP60), which is overexpressed in active BD lesions and may function as an autoantigen [3,6,67]. In this context, infectious agents may amplify innate immune activation and precipitate a Behçet-like phenotype, especially in individuals carrying susceptibility factors such as HLA-B51.
MT-associated BLS represents the best-documented infectious subgroup. These cases predominantly affect women, with a median onset age of approximately 45 years, and typically present with bipolar aphthosis, erythema nodosum, joint involvement, and ocular inflammation. The temporal relationship between tuberculosis and BLS varies considerably: symptoms may arise concurrently with active infection, years after its onset, or—less commonly—precede the diagnosis of MT infection. This variability highlights the need to consider occult or past infections when evaluating Behçet-like presentations.
Several viral pathogens—including HIV, EBV, HSV, and SARS-CoV-2—have also been implicated in BLS [31,32,33,34,68]. Compared with MT-related cases, viral BLS tends to have a shorter latency between infection and symptom onset. Fever, oral aphthosis, and pseudofolliculitis-like lesions were consistently reported across viral cases, while ocular inflammation was frequent, but major organ involvement was generally absent. The predominance of mucocutaneous and systemic inflammatory features suggests that viral infections may act as potent but transient immune triggers.
From a clinical perspective, these findings underscore the importance of identifying infectious etiologies before initiating immunosuppression. In most cases, targeted antimicrobial therapy leads to improvement of Behçet-like symptoms, confirming the reactive nature of the inflammatory process. However, persistent inflammation after pathogen eradication may require adjunctive immunomodulation, and TNF inhibitors have been used successfully in selected cases [47,68]. Recognizing infection-related BLS is therefore essential to avoid misdiagnosis, prevent inappropriate treatment, and ensure timely management of the underlying infection.

4.3. Myeloproliferative Disorders-Related Behçet-like Syndrome

Proinflammatory cytokines, including IL-1β, TNF-α, and IL-18, play a pivotal role in the pathogenesis of BD [2,5,44,46,69]. In myeloproliferative neoplasms (MPN), which are frequently associated with BD-like symptoms, there is a significant increase in inflammatory cytokine production [70,71], contributing to the chronic inflammatory state observed in affected patients. The interaction between myelodysplastic cells and T-cells may also play a key role in the development of autoimmune features in MPN-associated BLS. Forty-four cases of hematologic neoplasms with BLS have been reported, predominantly in Japanese patients (median age: 68 years). Most cases exhibited an incomplete BD phenotype [42,43,49,72,73,74,75], particularly the intestinal variant, frequently associated with trisomy 8 in myelodysplastic syndrome (MDS). Intestinal involvement (68%) was complicated by obstructions or stenosis in 18% of cases [45,50].
Chemotherapeutic treatment and immunosuppressive therapy, including prednisolone, cyclosporine A, TNF-α inhibitors, and mesalazine, provided symptom relief but were often insufficient for complete disease control. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) successfully treated both MDS and BD-like symptoms in two cases, suggesting its potential as a curative option. Moreover, the literature data report that immunosuppressive therapies such as ruxolitinib may alleviate BLS symptoms in MPN patients [7,51,76,77,78,79,80,81,82]. Overall, these findings emphasize that gastrointestinal Behçet-like disease in older adults—particularly when accompanied by cytopenias or systemic inflammation—should prompt evaluation for underlying MDS or MPN. Early recognition is essential, as management differs substantially from classical BD and may require hematologic intervention.

4.4. BLS, Paradoxical Reactions, and BD Exacerbations Induced by Biological Therapies

Cytokine imbalance may also underlie paradoxical Behçet-like reactions induced by biologic therapies [3,4,48,83,84]. De novo BD or exacerbations of pre-existing BD have been reported following treatment with several biologic agents, particularly anti-IL-17 therapies such as secukinumab and ixekizumab [22,23,24,25,29,85,86,87,88,89,90]. Similar Behçet-like presentations have been described as immune-related adverse events (irAEs) associated with immune checkpoint inhibitors [3,30,91], reflecting the profound immune modulation induced by these treatments.
Clinical manifestations in paradoxical BLS are heterogeneous but frequently include fever and skin lesions (50%), as well as oral and genital ulcers (87% and 75%, respectively). Anterior uveitis and gastrointestinal involvement were reported in 25% and 37.5% of cases, respectively, indicating that paradoxical reactions may reproduce the full spectrum of BD-like inflammation.
These observations have important clinical implications. Patients receiving biologic therapies should be monitored closely for new mucocutaneous or ocular symptoms, as early recognition and timely discontinuation of the offending agent can prevent progression and reduce morbidity [4,22,23,25,29]. Corticosteroids remain the mainstay of treatment and lead to symptom resolution in most cases [12,13,14,15,25]. In selected situations, switching to an alternative biologic class may be necessary to maintain control of the underlying disease while avoiding recurrence of Behçet-like manifestations.

4.5. Strengths and Limitations

This review is, to our knowledge, the first to comprehensively synthesize all published cases of BLS up to January 2024. Despite the heterogeneity of the included reports, the aggregated data offer valuable insights into the mechanisms that generate Behçet-like phenotypes and help delineate clinically relevant subgroups.
However, the evidence is inherently limited. All data derive from case reports and small case series, which are subject to publication bias, incomplete reporting, and variability in diagnostic work-up. Clinical features were not uniformly described, and histopathologic confirmation was often lacking. As a result, frequency estimates and inter-group comparisons should be interpreted cautiously, and causal relationships cannot be inferred.
The overlap between BD and BLS also raises conceptual questions. The low prevalence of HLA-B51 positivity and the incomplete penetrance observed in familial BD suggest that genetic background alone does not determine phenotype [17,18,19,20,21,52,56,57,58,59,60,61,62,63,64,65,92]. Environmental triggers, infections, hematologic disorders, and cytokine dysregulation likely modulate disease expression, supporting the idea of a spectrum rather than a strict dichotomy (Figure 3).
Figure 3. Simplified etiopathogenetic hypothesis of Behcet’s disease spectrum.

4.6. Practical Recommendations for Clinicians

Based on the patterns identified in this review, several practical considerations emerge:
Suspect BLS rather than BD when Behçet-like features occur with cytopenias, recurrent infections, early-onset autoinflammation, or recent exposure to biologics.
Investigate monogenic autoinflammatory diseases (A20, RELA, DADA2, NEMO) in early-onset or familial cases with prominent mucocutaneous involvement.
Evaluate for myelodysplastic syndromes, particularly trisomy 8, in patients with intestinal ulcers, unexplained cytopenias, or poor response to BD-oriented therapy.
Consider infectious triggers—especially tuberculosis and chronic viral infections—when fever and erythema nodosum predominate.
Tailor treatment to the underlying etiology, as management differs substantially from classical BD.
Monitor for paradoxical reactions in patients receiving IL-17 inhibitors or immune checkpoint inhibitors.
Recognizing BLS as a distinct clinical construct is essential to avoid misdiagnosis, prevent inappropriate immunosuppression, and guide targeted therapy. Moreover, the study of BLS may provide valuable insights into BD pathogenesis and help identify new therapeutic targets.

5. Conclusions

This extensive literature review highlights the characteristics of the different entities included in BLS, related to classical and recently described autoinflammatory syndromes, myeloproliferative diseases, viral and mycobacterial infections, as well as paradoxical reactions secondary to drug treatment. The typical clinical manifestations of BD help us to conceptualize that BD is the expression of a complex cytokine balance disorder, in the context of a genetic predisposition, sometimes influenced by environmental factors, and with possible interactions with other inflammatory pathways.
Given the potential severity of BLS, being aware of the different BLS entities described in this article is fundamental for the correct management of patients. Furthermore, the development of effective therapeutic strategies remains an urgent priority. Future research focusing on the molecular mechanisms underlying immune dysregulation in BLS is essential to identify optimal targeted treatments and improve patient outcomes.

Author Contributions

G.M. and H.B.: study concept and design, acquisition, analysis and interpretation of data, and drafting of the manuscript. G.M.: collection, analysis, and interpretation of clinical data. I.S., A.O., B.B. and H.B.: critical review of the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Data Availability Statement

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Perazzio, S.F.; Allenspach, E.J.; Eklund, K.K.; Varjosalo, M.; Shinohara, M.M.; Torgerson, T.R.; Seppänen, M.R.J. Behçet disease (BD) and BD-like clinical phenotypes: NF-κB pathway in mucosal ulcerating diseases. Scand. J. Immunol. 2020, 92, e12973. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  2. Koba, S.; Sekioka, T.; Takeda, S.; Miyagawa-Hayashino, A.; Nishimura, K.; Imashuku, S. Acute Monocytic Leukemia Masquerading Behçet’s Disease-Like Illness at Onset in an Elderly Female. Case Rep. Hematol. 2016, 2016, 4231276. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  3. Yazici, Y.; Hatemi, G.; Bodaghi, B.; Cheon, J.H.; Suzuki, N.; Ambrose, N.; Yazici, H. Behçet syndrome. Nat. Rev. Dis. Primers. 2021, 7, 67. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  4. Dincses, E.; Yurttas, B.; Esatoglu, S.N.; Melikoglu, M.; Hamuryudan, V.; Seyahi, E. Secukinumab induced Behçet’s syndrome: A report of two cases. Oxf. Med. Case Rep. 2019, 2019, omz041. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  5. Ishikawa, Y.; Sasaki, R.; Ishiwata, A.; Hatakeyama, S.; Matsumura, M.; Sato, T. A case of Behçet’s-like disease associated with trisomy 8-positive myelodysplastic syndrome carrying MEFV E148Q variant presented with periodic fever. Mod. Rheumatol. Case Rep. 2023, 7, 470–474. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  6. Zhang, D.; Su, G.; Zhou, Z.; Lai, J. Clinical characteristics and genetic analysis of A20 haploinsufficiency. Pediatr. Rheumatol. Online J. 2021, 19, 75. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  7. Hatemi, G.; Seyahi, E.; Fresko, I.; Talarico, R.; Uçar, D.; Hamuryudan, V. Behçet’s syndrome: One year in review 2024. Clin. Exp. Rheumatol. 2024, 42, 1999–2007. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  8. Taskiran, E.Z.; Sonmez, H.E.; Kosukcu, C.; Tavukcuoglu, E.; Yazici, G.; Esendagli, G.; Batu, E.D.; Kiper, P.O.S.; Bilginer, Y.; Alikasifoglu, M.; et al. A Novel Missense LIG4 Mutation in a Patient with a Phenotype Mimicking Behçet’s Disease. J. Clin. Immunol. 2019, 39, 99–105. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  9. Kiafar, M.; Faezi, S.T.; Kasaeian, A.; Baghdadi, A.; Kakaei, S.; Mousavi, S.A.; Nejadhosseinian, M.; Shahram, F.; Ghodsi, S.Z.; Shams, H.; et al. Diagnosis of Behçet’s disease: Clinical characteristics, diagnostic criteria, and differential diagnoses. BMC Rheumatol. 2021, 5, 2. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  10. Nara, K.; Kurokawa, M.S.; Chiba, S.; Yoshikawa, H.; Tsukikawa, S.; Matsuda, T.; Suzuki, N. Involvement of innate immunity in the pathogenesis of intestinal Behçet’s disease. Clin. Exp. Immunol. 2008, 152, 245–251. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  11. Dong, X.; Liu, L.; Wang, Y.; Yang, X.; Wang, W.; Lin, L.; Sun, B.; Hou, J.; Ying, W.; Hui, X.; et al. Novel Heterogeneous Mutation of TNFAIP3 ina Chinese Patient with Behçet-Like Phenotype and Persistent EBV Viremia. J. Clin. Immunol. 2019, 39, 188–194. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  12. Zhou, Q.; Wang, H.; Schwartz, D.M.; Stoffels, M.; Park, Y.H.; Zhang, Y.; Yang, D.; Demirkaya, E.; Takeuchi, M.; Tsai, W.L.; et al. Loss-of-function mutations in TNFAIP3 leading to A20 haploinsufficiency cause an early-onset autoinflammatory disease. Nat. Genet. 2016, 48, 67–73. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  13. Adeeb, F.; Dorris, E.R.; Morgan, N.E.; Lawless, D.; Maqsood, A.; Ng, W.L.; Killeen, O.; Cummins, E.P.; Taylor, C.T.; Savic, S.; et al. A Novel RELA Truncating Mutation in a Familial Behçet’s Disease-like Mucocutaneous Ulcerative Condition. Arthritis Rheumatol. 2021, 73, 490–497. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  14. Chen, Y.; Huang, H.; He, Y.; Chen, M.; Seidler, U.; Tian, D.; Xiao, F. A20 Haploinsufficiency in a Chinese Patient with Intestinal Behcet’s Disease-Like Symptoms: A Case Report. Front. Immunol. 2020, 11, 1414. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  15. An, J.W.; Pimpale-Chavan, P.; Stone, D.L.; Bandeira, M.; Dedeoglu, F.; Lo, J.; Bohnsack, J.; Rosenzweig, S.; Schnappauf, O.; Dissanayake, D.; et al. Case report: Novel variants in RELA associated with familial Behcet’s-like disease. Front. Immunol. 2023, 14, 1127085. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  16. Eyre, S.; Hinks, A.; Bowes, J.; Flynn, E.; Martin, P.; Wilson, A.G.; Morgan, A.W.; Emery, P.; Steer, S.; Hocking, L.J.; et al. Overlapping genetic susceptibility variants between three autoimmune disorders: Rheumatoid arthritis, type 1 diabetes and coeliac disease. Arthritis Res. Ther. 2010, 12, R175. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  17. Tsuchida, N.; Kirino, Y.; Soejima, Y.; Onodera, M.; Arai, K.; Tamura, E.; Ishikawa, T.; Kawai, T.; Uchiyama, T.; Nomura, S.; et al. Haploinsufficiency of A20 caused by a novel nonsense variant or entire deletion of TNFAIP3 is clinically distinct from Behçet’s disease. Arthritis Res. Ther. 2019, 21, 137. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  18. Baldini, L.; Di Sabatino, F.; Bodrero, E.; Dellepiane, M.; Covizzi, C.; La Selva, R.; Montin, D.; Licciardi, F. NeMO mutations: A rare cause of monogenic Behçet-like disease. Rheumatology 2021, 60, e92–e94. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  19. Dimopoulou, C.; Lundgren, J.D.; Sundal, J.; Ullum, H.; Aukrust, P.; Nielsen, F.C.; Marvig, R.L. Variant in ERAP1 promoter region is associated with low expression in a patient with a Behçet-like MHC-I-opathy. J. Hum. Genet. 2020, 65, 325–335. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  20. van Well, G.T.J.; Kant, B.; van Nistelrooij, A.; Sirma Ekmekci, S.; Henriet, S.V.; Hoppenreijs, E.; van Deuren, M.; van Montfrans, J.; Nierkens, S.; Gül, A.; et al. Phenotypic variability including Behçet’s disease-like manifestations in DADA2 patients due to a homozygous c.973-2A>G splice site mutation. Clin. Exp. Rheumatol. 2019, 37, 142–146. [Google Scholar] [PubMed]
  21. Rösler, B.; Heinhuis, B.; Wang, X.; Silvestre, R.; Joosten, L.A.B.; Netea, M.G.; Arts, P.; Mantere, T.; Lefeber, D.J.; Hoischen, A.; et al. Mimicking Behçet’s disease: GM-CSF gain of function mutation in a family suffering from a Behçet’s disease-like disorder marked by extreme pathergy. Clin. Exp. Immunol. 2021, 204, 189–198. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  22. Calleja Algarra, A.; Aragón Miguel, R.; Andrés Lencina, J.J.; Pinilla Martín, B.; Vico Alonso, C.; Rodríguez Peralto, J.L.; Ortiz Romero, P.L.; Rivera Díaz, R. Behçet’s-like disease during secukinumab treatment: New paradoxical reaction? J. Dtsch. Dermatol. Ges. 2021, 19, 116–118. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  23. Avcı, C.; Akın, G.; Akarsu, S.; Lebe, B. Pyoderma gangrenosum and Behçet’s-like disease induced by secukinumab: A paradoxical drug reaction. J. Dermatolog. Treat. 2023, 34, 2235040. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  24. Barrado-Solís, N.; Rodrigo-Nicolás, B.; De la Morena-Barrio, I.; Pérez-Pastor, G.; Sanchis-Sánchez, C.; Tomás-Cabedo, G.; Valcuende-Cavero, F. Report of two cases of Behçet’s disease developed during treatment with secukinumab. J. Eur. Acad. Dermatol. Venereol. 2020, 34, e587–e589. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  25. Shiga, H.; Fukuda, S.; Iijima, K. Interleukin-17A Inhibitor-induced Crohn’s Disease/Behçet’s Disease-like Lesions. Inflamm. Bowel Dis. 2017, 23, E38–E39. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  26. Endoh, M.; Yokozeki, H.; Maruyama, R.; Matsunaga, T.; Katayama, I.; Nishioka, K. Incontinentia pigmenti and Behçet’s disease: A case of impaired neutrophil chemotaxis. Dermatology 1996, 192, 285–287. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  27. Márquez Balbás, G.; González-Enseñat, M.A.; Vicente, A.; Creus-Vila, L.; Antón, J.; Umbert-Millet, P. Incontinentia pigmenti and bipolar aphthosis: An unusual combination. ISRN Dermatol. 2011, 2011, 814186. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  28. Buskila, D.; Gladman, D.D.; Gilmore, J.; Salit, I.E. Behçet’s disease in a patient with immunodeficiency virus infection. Ann. Rheum. Dis. 1991, 50, 115–116. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  29. Chen, D.; Zhou, M.; Xu, A.; Zheng, J.; Lu, L. Behcet’s-like disease in a patient treated with Ixekizumab for chronic plaque psoriasis. Scand. J. Rheumatol. 2022, 51, 336–337. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  30. Thomas, S.; Bae, C.; Joy-Ann, T.; Traverse, W. Behcet’s-like syndrome following pembrolizumab: An immune-related adverse event associated with programmed death receptor-1 inhibitor therapy. J. Oncol. Pharm. Pract. 2020, 26, 995–999. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  31. Fukui, S.; Takizawa, Y.; Kubota, N.; Okamoto, T.; Hishima, T. Tuberculous lymphadenitis and the appearance of Behçet’s disease-like symptoms. Intern. Med. 2014, 53, 805–808. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  32. Shinoda, K.; Hayashi, R.; Taki, H.; Hounoki, H.; Makino, T.; Nomoto, K.; Shimizu, T.; Tobe, K. Pseudo-Behçet’s disease associated with tuberculosis: A case report and review of the literature. Rheumatol. Int. 2014, 34, 1471–1474. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  33. Sharma, A.; Dogra, S.; Pinto, B.; Sharma, K.; Singh, R.; Dhir, V.; Sharma, S.K.; Kakkar, N.; Radotra, B.; Singh, S. Poncet’s disease presenting as Pseudo-Behçet’s disease. Int. J. Rheum. Dis. 2013, 16, 483–485. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  34. Zhang, L.; Xu, Y.; Peng, Y.; Yan, B.; Liu, Y. Behçet’s disease-like syndrome secondary to microbial infection: A case report and review of the literature. Int. J. Clin. Exp. Pathol. 2015, 8, 13619–13624. [Google Scholar] [PubMed] [PubMed Central]
  35. Yamaoka, T.; Takahashi, S.; Ijuin, K.; Nagai, H.; Kumagai, S. A case of pemphigus vulgaris with folliculitis-like nodules, genital and oral ulcers difficult to differentiate from Behçet’s disease. Clin. Exp. Rheumatol. 2023, 41, 2128. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  36. Venzor, J.; Hua, Q.; Bressler, R.B.; Miranda, C.H.; Huston, D.P. Behçet’s-like syndrome associated with idiopathic CD4+ T-lymphocytopenia, opportunistic infections, and a large population of TCR alpha beta+ CD4- CD8- T cells. Am. J. Med. Sci. 1997, 313, 236–238. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  37. Park, B.M.; Ahn, J.S.; Lee, J.B.; Won, Y.H.; Yun, S.J. Chronic active Epstein-Barr virus infection-associated hydroa vacciniforme-like eruption and Behçet’s-like orogenital ulcers. Dermatology 2013, 226, 212–216. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  38. Obama, K.; Yamamoto, H.; Inoue, H. Behçet’s disease-like clinical manifestations of chronic lymphocytic leukemia during good response to ibrutinib. EJHaem 2023, 4, 859–860. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  39. Koguchi-Yoshioka, H.; Inokuma, D.; Kanda, M.; Kondo, M.; Kikuchi, K.; Shimizu, S. Behçet’s disease-like symptoms associated with myelodysplastic syndrome with trisomy 8: A case report and review of the literature. Acta Derm. Venereol. 2014, 94, 355–356. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  40. Tagini, F.; Carrel, L.; Fallet, B.; Gachoud, D.; Ribi, C.; Monti, M. Behçet’s-like adverse event or inaugural Behçet’s disease after SARS-CoV-2 mRNA-1273 vaccination? Rheumatology 2022, 61, e112–e113. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  41. Tanaka, N.; Sakuraba, H.; Hiraga, H.; Mayama, K.; Kikuchi, H.; Kishida, D.; Akemoto, Y.; Hasui, K.; Ota, S.; Watanabe, R.; et al. Long-term maintenance of the mucosal healing induced by azacitidine therapy in a patient with intestinal Behçet’s-like disease accompanied with myelodysplastic syndrome involving trisomy 8. Immunol. Med. 2019, 42, 135–141. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  42. Wang, S.; Broder, N.; Marchetta, P.; Nowatzky, J. Myelodysplastic syndrome presenting as a Behçet’s-like disease with aortitis. BMJ Case Rep. 2018, 2018, bcr2017220649. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  43. Mori, Y.; Iwamoto, F.; Kuno, T.; Kobayashi, S.; Yoshida, T.; Yamaguchi, T.; Takano, S.; Kondo, T.; Kirito, K.; Enomoto, N. Trisomy 8-positive Polycythemia Vera Complicated with Intestinal Behçet’s-like Disease: A New Perspective for a Clinical Approach. Intern. Med. 2022, 61, 1713–1719. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  44. Oka, S.; Ono, K.; Nohgawa, M. The acquisition of trisomy 8 associated with Behçet’s-like disease in myelodysplastic syndrome. Leuk. Res. Rep. 2020, 13, 100196. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  45. Takahashi, N.; Hanajiri, R.; Suzuki, M.; Anan, C.; Inagaki, A.; Kishida, D.; Ozawa, S.; Kohri, S.; Kamiya, N.; Sato, M.; et al. Myelodysplastic syndrome with trisomy 8 presenting periodic fever and multiple MEFV gene variants outside exon 10: A case report. Nagoya J. Med. Sci. 2023, 85, 195–203. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  46. Endo, M.; Sekikawa, A.; Tsumura, T.; Maruo, T.; Osaki, Y. A Case of Myelodysplastic Syndrome with Intestinal Behçet’s Disease-Like Symptoms Treated by Prednisolone and Azacitidine. Am. J. Case Rep. 2015, 16, 827–831. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  47. Sugata, K.; Enomoto, Y.; Sugiyama, H.; Fujita, A.; Miyake, F.; Asano, Y.; Yoshikawa, T. Single episode of Behcet’s disease-like symptoms caused by herpes simplex virus reactivation. Pediatr. Int. 2009, 51, 577–578. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  48. Krečak, I.; Šupe, M.; Ilić, I.; Gverić-Krečak, V. Behçet-like syndrome associated with aplastic anemia successfully treated with mycophenolate mofetil. Ann. Hematol. 2021, 100, 2411–2413. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  49. Matsumoto, Y.; Ota, K.; Yamada, H. Gastrointestinal: Intestinal Behçet’s disease- like ulcers associated with myelodysplastic syndrome with monosomy 7. J. Gastroenterol. Hepatol. 2019, 34, 310. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  50. Wesner, N.; Drevon, L.; Guedon, A.; Fraison, J.B.; Terrier, B.; Trad, S.; Kahn, J.E.; Aouba, A.; Gillard, J.; Ponsoye, M.; et al. Gastrointestinal Behcet’s-like disease with myelodysplastic. Lymphoma 2019, 60, 1782–1788. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  51. Liu, Z.; Yang, C.; Bai, X.; Shen, K.; Qiao, L.; Wang, Q.; Yang, H.; Qian, J. Clinical features and prognosis of patients with gastrointestinal Behçet’s disease-like syndrome and myelodysplastic syndrome with and without trisomy 8. Semin. Arthritis Rheum. 2022, 55, 152039. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  52. Takada, H.; Nomura, A.; Ishimura, M.; Ichiyama, M.; Ohga, S.; Hara, T. NEMO mutation as a cause of familial occurrence of Behçet’s disease in female patients. Clin. Genet. 2010, 78, 575–579. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  53. Juan, C.K.; Shen, J.L.; Yang, C.S.; Liu, K.L.; Chen, Y.J. Flare-up of incontinentia pigmenti in association with Behçet disease. J Dtsch. Dermatol. Ges. 2015, 13, 154–156. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  54. Lin, H.K.; Fu, L.S. Concurrence of Incontinentia Pigmenti and Behçet’s Disease. J. Chin. Med. Assoc. 2010, 73, 275–278. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  55. Choudhary, S.; Srivastava, A.; Varadharajan, A.; Choudhary, R. Multiple cutaneous and mucocutaneous lesions as manifestations of pseudo-Behçet’s disease. BMJ Case Rep. 2023, 16, e255669. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  56. Davatchi, F. Diagnosis/Classification Criteria for Behcet’s Disease. Patholog. Res. Int. 2012, 2012, 607921. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  57. Di Cianni, F.; Sulis, A.; Italiano, N.; Moretti, M.; Urban, M.L.; Ferro, F.; Emmi, G.; Cutolo, M.; Mosca, M.; Talarico, R. The impact of environmental factors on aetiopathogenesis and clinical manifestations of Behçet’s syndrome. Clin. Exp. Rheumatol. 2024, 42, 2008–2013. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  58. Zhang, L.W.; Wu, J. Incontinentia Pigmenti. J. Cutan. Med. Surg. 2024, 28, 210. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  59. Blonska, M.; Lin, X. NF-κB signaling pathways regulated by CARMA family of scaffold proteins. Cell Res. 2011, 21, 55–70. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  60. Badran, Y.R.; Dedeoglu, F.; Leyva Castillo, J.M.; Bainter, W.; Ohsumi, T.K.; Bousvaros, A.; Goldsmith, J.D.; Geha, R.S.; Chou, J. Human RELA haploinsufficiency results in autosomal-dominant chronic mucocutaneous ulceration. J. Exp. Med. 2017, 214, 1937–1947. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  61. Shigemura, T.; Kaneko, N.; Kobayashi, N.; Kobayashi, K.; Takeuchi, Y.; Nakano, N.; Masumoto, J.; Agematsu, K. Novel heterozygous C243Y A20/TNFAIP3 gene mutation is responsible for chronic inflammation in autosomal-dominant Behçet’s disease. RMD Open 2016, 2, e000223. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  62. Papadopoulou, C.; Omoyinmi, E.; Standing, A.; Pain, C.E.; Booth, C.; D’Arco, F.; Gilmour, K.; Buckland, M.; Eleftheriou, D.; Brogan, P.A. Monogenic mimics of Behçet’s disease in the young. Rheumatology 2019, 58, 1227–1238. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  63. Hattori, A.; Tsujimoto, M. Endoplasmic reticulum aminopeptidases: Biochemistry, physiology and pathology. J. Biochem. 2013, 154, 219–228. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  64. Khoshbakht, S.; Başkurt, D.; Vural, A.; Vural, S. Behçet’s Disease: A Comprehensive Review on the Role of HLA-B*51, Antigen Presentation, and Inflammatory Cascade. Int. J. Mol. Sci. 2023, 24, 16382. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  65. Zhang, L.; Yu, H.; Zheng, M.; Li, H.; Liu, Y.; Kijlstra, A.; Yang, P. Association of ERAP1 Gene Polymorphisms with Behçet’s Disease in Han Chinese. Invest. Ophthalmol. Vis. Sci. 2015, 56, 6029–6035. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  66. Lee, P.Y.; Davidson, B.A.; Abraham, R.S.; Alter, B.; Arostegui, J.I.; Bell, K.; Belot, A.; Bergerson, J.R.E.; Bernard, T.J.; Brogan, P.A.; et al. Evaluation and Management of Deficiency of Adenosine Deaminase 2: An International Consensus Statement. JAMA Netw. Open. 2023, 6, e2315894. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  67. Glaser, R.L.; Goldbach-Mansky, R. The spectrum of monogenic autoinflammatory syndromes: Understanding disease mechanisms and use of targeted therapies. Curr. Allergy Asthma Rep. 2008, 8, 288–298. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  68. Eglin, R.P.; Lehner, T.; Subak-Sharpe, J.H. Detection of RNA complementary to herpes-simplex virus in mononuclear cells from patients with Behçet’s syndrome and recurrent oral ulcers. Lancet 1982, 2, 1356–1361. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  69. Yazici, H.; Seyahi, E.; Hatemi, G.; Yazici, Y. Behçet syndrome: A contemporary view. Nat. Rev. Rheumatol. 2018, 14, 107–119, Erratum in Nat. Rev. Rheumatol. 2018, 14, 119. https://doi.org/10.1038/nrrheum.2018.3. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  70. Chen, G.; Zeng, W.; Miyazato, A.; Billings, E.; Maciejewski, J.P.; Kajigaya, S.; Sloand, E.M.; Young, N.S. Distinctive gene expression profiles of CD34 cells from patients with myelodysplastic syndrome characterized by specific chromosomal abnormalities. Blood 2004, 104, 4210–4218. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  71. Fraison, J.B.; Mekinian, A.; Grignano, E.; Kahn, J.E.; Arlet, J.B.; Decaux, O.; Denis, G.; Buchdahl, A.L.; Omouri, M.; Maigne, G.; et al. Efficacy of Azacitidine in autoimmune and inflammatory disorders associated with myelodysplastic syndromes and chronic myelomonocytic leukemia. Leuk. Res. 2016, 43, 13–17. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  72. Sánchez-Abarca, L.I.; Gutierrez-Cosio, S.; Santamaría, C.; Caballero-Velazquez, T.; Blanco, B.; Herrero-Sánchez, C.; García, J.L.; Carrancio, S.; Hernández-Campo, P.; González, F.J.; et al. Immunomodulatory effect of 5-azacytidine (5-azaC): Potential role in the transplantation setting. Blood 2010, 115, 107–121. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  73. Estey, E.H. Epigenetics in clinical practice: The examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia. Leukemia 2013, 27, 1803–1812. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  74. Handa, T.; Arai, Y.; Mitani, K. Myelodysplastic syndrome associated with intestinal tract-type Behçet disease characterized by an esophageal ulcer. Rinsho Ketsueki 2004, 45, 1135–1137. (In Japanese) [Google Scholar] [PubMed]
  75. Tada, Y.; Koarada, S.; Haruta, Y.; Mitamura, M.; Ohta, A.; Nagasawa, K. The association of Behçet’s disease with myelodysplastic syndrome in Japan: A review of literature. Clin. Exp. Rheumatol. 2006, 24, S115–S119, Erratum in Clin. Exp. Rheumatol. 2007, 25, 507–508. [Google Scholar] [PubMed]
  76. Ostojic, A.; Vrhovac, R.; Verstovsek, S. Ruxolitinib: A new JAK1/2 inhibitor that offers promising options for treatment of myelofibrosis. Future Oncol. 2011, 7, 1035–1043. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  77. Liu, E.; Aslam, N.; Nigam, G.; Limdi, J.K. Tofacitinib and newer JAK inhibitors in inflammatory bowel disease-where we are and where we are going. Drugs Context 2022, 11, 1–17. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  78. Narazaki, T.; Shiratsuchi, M.; Tsuda, M.; Tsukamoto, Y.; Muta, H.; Masuda, T.; Kimura, D.; Takamatsu, A.; Nakanishi, R.; Oki, E.; et al. Intestinal Behçet’s Disease with Primary Myelofibrosis Involving Trisomy 8. Acta Haematol. 2019, 142, 253–256. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  79. Ishii, A.; Tsukamoto, S.; Mishina, T.; Izumi, S.; Nagai, Y.; Yamazaki, M.; Hino, Y.; Kayamori, K.; Oshima-Hasegawa, N.; Muto, T.; et al. Successful allogeneic bone marrow transplantation after massive gastrointestinal bleeding in a patient with myelodysplastic syndrome associated with intestinal Behçet-like disease. Leuk. Res. Rep. 2021, 16, 100278, Erratum in Leuk. Res. Rep. 2022, 17, 100309. https://doi.org/10.1016/j.lrr.2022.100309. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  80. Xu, H.; Liu, M.; Cao, J.; Li, X.; Fan, D.; Xia, Y.; Lu, X.; Li, J.; Ju, D.; Zhao, H. The Dynamic Interplay between the Gut Microbiota and Autoimmune Diseases. J. Immunol. Res. 2019, 2019, 7546047. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  81. Mendez Luque, L.F.; Blackmon, A.L.; Ramanathan, G.; Fleischman, A.G. Key Role of Inflammation in Myeloproliferative Neoplasms: Instigator of Disease Initiation, Progression. and Symptoms. Curr. Hematol. Malig. Rep. 2019, 14, 145–153. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  82. Calcinotto, A.; Brevi, A.; Chesi, M.; Ferrarese, R.; Garcia Perez, L.; Grioni, M.; Kumar, S.; Garbitt, V.M.; Sharik, M.E.; Henderson, K.J.; et al. Microbiota-driven interleukin-17-producing cells and eosinophils synergize to accelerate multiple myeloma progression. Nat. Commun. 2018, 9, 4832. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  83. Mattioli, I.; Bettiol, A.; Saruhan-Direskeneli, G.; Direskeneli, H.; Emmi, G. Pathogenesis of Behçet’s Syndrome: Genetic, Environmental and Immunological Factors. Front. Med. 2021, 8, 713052. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  84. Nanke, Y.; Yago, T.; Kotake, S. The Role of Th17 Cells in the Pathogenesis of Behcet’s Disease. J. Clin. Med. 2017, 6, 74. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  85. Leccese, P.; Alpsoy, E. Behçet’s Disease: An Overview of Etiopathogenesis. Front. Immunol. 2019, 10, 1067. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  86. Pavelka, K. Targeted and biological drugs in the treatment of inflammatory rheumatic diseases. Vnitr. Lek. 2021, 67, 195–200. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  87. Puig, L. Paradoxical Reactions: Anti-Tumor Necrosis Factor Alpha Agents, Ustekinumab, Secukinumab, Ixekizumab, and Others. Curr. Probl. Dermatol. 2018, 53, 49–63. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  88. Messina, F.; Piaserico, S. The dark side of the moon: The immune-mediated adverse events of IL-17A/IL-17R inhibition. J. Dermatolog. Treat. 2022, 33, 2443–2454. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  89. Di Scala, G.; Bettiol, A.; Cojan, R.D.; Finocchi, M.; Silvestri, E.; Emmi, G. Efficacy of the anti-IL 17 secukinumab in refractory Behçet’s syndrome: A preliminary study. J Autoimmun. 2019, 97, 108–113. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  90. Dick, A.D.; Tugal-Tutkun, I.; Foster, S.; Zierhut, M.; Melissa Liew, S.H.; Bezlyak, V.; Androudi, S. Secukinumab in the treatment of noninfectious uveitis: Results of three randomized, controlled clinical trials. Ophthalmology 2013, 120, 777–787. [Google Scholar] [CrossRef] [Scilit]
  91. Baxi, S.; Yang, A.; Gennarelli, R.L.; Khan, N.; Wang, Z.; Boyce, L.; Korenstein, D. Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: Systematic review and meta-analysis. BMJ 2018, 360, k793. [Google Scholar] [CrossRef] [Scilit] [PubMed] [PubMed Central]
  92. Koné-Paut, I.; Shahram, F.; Darce-Bello, M.; Cantarini, L.; Cimaz, R.; Gattorno, M.; Anton, J.; Hofer, M.; Chkirate, B.; Bouayed, K.; et al. Consensus classification criteria for paediatric Behçet’s disease from a prospective observational cohort: PEDBD. Ann. Rheum. Dis. 2016, 75, 958–964. [Google Scholar] [CrossRef] [Scilit] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Article Metrics

Citations

Article Access Statistics

Journal Statistics
Multiple requests from the same IP address are counted as one view.
Tumor Infiltrating Lymphocytes in Cutaneous Squamous Cell Carcinoma—A Systematic Review
Previous
The Unusual Invader in a Patient with Long-Standing Rheumatoid Arthritis: A Case of Leishmania major Colonization of Rheumatoid Nodules
Next